2026-06-14T03:42:47Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/184822024-11-28T14:49:13Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud
author
Moreno-Gonzalez, Ines
author
Edwards III, George A.
author
Hasan, Omar
author
Gamez, Nazaret
author
Schulz, Jonathan E.
author
Fernandez-Valenzuela, Juan Jose
author
Gutierrez, Antonia
author
Soto, Claudio
author
Schulz, Paul E.
authoraffiliation
[Moreno-Gonzalez,I; Edwards III,GA; Hasan,O; Gamez,N; Schulz,JE; Soto,C; Schulz,PE] Department of Neurology, The University of Texas Health Science Center at Houston, Houston, USA. [Moreno-Gonzalez,I; Gamez,N; Fernandez-Valenzuela,JJ; Gutierrez,A] Department of Cell Biology, Instituto de Investigacion Biomedica de Malaga-IBIMA, Faculty of Sicences, University of Malaga, Malaga, Spain. [Moreno-Gonzalez,I; Fernandez-Valenzuela,JJ; Gutierrez,A] Networking Biomedical Research Center on Neurodegenerative Diseases (CIBERBED), Madrid, Spain.
2024-02-19T15:31:42Z
2024-02-19T15:31:42Z
2021-10-12
10.3390/diagnostics11101874
2075-4418
Diagnostics
http://hdl.handle.net/10668/4483
34679572
http://hdl.handle.net/20.500.12105/18482
Several common and debilitating neurodegenerative disorders are characterized by the intracellular accumulation of neurofibrillary tangles (NFTs), which are composed of hyperphosphorylated tau protein. In Alzheimer's disease (AD), NFTs are accompanied by extracellular amyloid-beta (Aβ), but primary tauopathy disorders are marked by the accumulation of tau protein alone, including forms of frontotemporal dementia (FTD), corticobasal degeneration (CBD), and progressive supranuclear palsy (PSP), among others. 18F-THK5351 has been reported to bind pathological tau as well as associated reactive astrogliosis. The goal of this study was to validate the ability of the PET tracer 18F-THK5351 to detect early changes in tau-related pathology and its relation to other pathological hallmarks. We demonstrated elevated in vivo 18F-THK5351 PET signaling over time in transgenic P301S tau mice from 8 months that had a positive correlation with histological and biochemical tau changes, as well as motor, memory, and learning impairment. This study indicates that 18F-THK5351 may help fill a critical need to develop PET imaging tracers that detect aberrant tau aggregation and related neuropathology in order to diagnose the onset of tauopathies, gain insights into their underlying pathophysiologies, and to have a reliable biomarker to follow during treatment trials.
eng
PET imaging
Tau
THK5351
Tracer
Biomarker
Histological assessment
Cognitive impairment
Tauopathy
Alzheimer’s disease
Dementia
Tomografía por emisión de positrones
Proteínas tau
Trazadores radiactivos
Biomarcadores
Técnicas histológicas
Disfunción cognitiva
Tauopatías
Enfermedad de Alzheimer
Demencia
Longitudinal Assessment of Tau-Associated Pathology by 18F-THK5351 PET Imaging: A Histological, Biochemical, and Behavioral Study
research article